ITK inhibition induced in vitro and in vivo anti-tumor activity through downregulating TCR signaling pathway in malignant T cell lymphoma

Table 1 Clinical characteristics of AITL patients and correlations with the expression of phosphorylated ITK

Clinical parameters	No.	p-ITK		P
Clinical parameters	No.	Positive	Negative	P
Gender
Male	27	21	6
Female	11	8	3	1
Age
≤ 60	20	17	3
> 60	18	12	6	0.26
Stage
III	14	10	4
IV	22	17	5	0.712
IPI score
0–2	18	16	2
3–5	18	11	7	0.121
ECOG
0–1	34	26	8
2–3	1	0	1	0.257
Ki-67
< 75%	31	24	7
≥ 75%	4	2	2	0.268
Extranodal invasion
≤ 2	12	9	3
> 2	24	18	6	1
EBER
Positive	28	20	8
Negative	7	6	1	0.648
B symptoms
Positive	20	14	6
Negative	17	14	3	0.462
LDH
Positive	25	18	7
Negative	11	9	2	0.69
β2-MG
Positive	19	13	6
Negative	13	12	1	0.195
ESR
Positive	17	13	4
Negative	12	9	3	1
BM involvement
Positive	6	6	0
Negative	29	20	9	0.304
Clinical response
CR	11	5	6
PR + SD + PD	22	20	2	0.004

ISSN: 1475-2867